Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Slični predmeti

• Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
  od: Diana L. Price, i dr.
  Izdano: (2024-03-01)
• Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
  od: Michel Alexander Steiner
  Izdano: (2024-03-01)
• The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
  od: Diana L. Price, i dr.
  Izdano: (2018-11-01)
• Effect of spermidine on misfolding and interactions of alpha-synuclein.
  od: Alexey V Krasnoslobodtsev, i dr.
  Izdano: (2012-01-01)
• Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders
  od: Jose Miguel Flores‐Fernandez, i dr.
  Izdano: (2024-07-01)